Compare JG & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JG | KYNB |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 32.8M |
| IPO Year | 2018 | 2014 |
| Metric | JG | KYNB |
|---|---|---|
| Price | $7.00 | $6.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 2.6K | ★ 28.0K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,440,000.00 |
| Revenue This Year | N/A | $4.23 |
| Revenue Next Year | N/A | $14.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.20 | $5.62 |
| 52 Week High | $8.58 | $9.58 |
| Indicator | JG | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 35.41 |
| Support Level | $6.25 | N/A |
| Resistance Level | $8.32 | $7.41 |
| Average True Range (ATR) | 0.30 | 0.32 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 91.89 | 38.10 |
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates in one segment and generates revenues from SAAS Businesses.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.